Cargando…

Janus kinase inhibitors in autoimmune bullous diseases

Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins. Currently, the preferred treatment for AIBD involves the use of glucocorticoids or traditional immunosuppressants. Additionally, the utilization of biologi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Dawei, Zhang, Yuexin, Kong, Luyang, Lu, Jiajing, Shi, Yuling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363722/ https://www.ncbi.nlm.nih.gov/pubmed/37492565 http://dx.doi.org/10.3389/fimmu.2023.1220887

Ejemplares similares

Development of bullous pemphigoid during treatment of psoriasis with ustekinumab: a case report and literature review
por: Kong, Luyang, et al.
Publicado: (2023)

Targeting the Janus Kinase Family in Autoimmune Skin Diseases
por: Howell, Michael D., et al.
Publicado: (2019)

Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
por: Nash, David, et al.
Publicado: (2022)

Janus Kinase Inhibitors and Cell Therapy
por: Assal, Amer, et al.
Publicado: (2021)

Humoral Epitope Spreading in Autoimmune Bullous Diseases
por: Didona, Dario, et al.
Publicado: (2018)

Serological Diagnosis of Autoimmune Bullous Skin Diseases
por: Saschenbrecker, Sandra, et al.
Publicado: (2019)

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
por: Qi, Fei, et al.
Publicado: (2021)

Retrospective analysis of autoimmune bullous diseases in Middle Franconia
por: Sollfrank, Lukas, et al.
Publicado: (2023)

Understanding CD4(+) T cells in autoimmune bullous diseases
por: Lee, A Yeong, et al.
Publicado: (2023)

Absolving COVID-19 Vaccination of Autoimmune Bullous Disease Onset
por: Russo, Roberto, et al.
Publicado: (2022)

Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway
por: Dang, Chun, et al.
Publicado: (2021)

BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid
por: Liu, Yale, et al.
Publicado: (2017)

The Role of Mast Cells in Autoimmune Bullous Dermatoses
por: Yu, Xinhua, et al.
Publicado: (2018)

The Janus Head of T Cell Aging – Autoimmunity and Immunodeficiency
por: Goronzy, Jörg J., et al.
Publicado: (2013)

Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
por: Kubo, Satoshi, et al.
Publicado: (2018)

Molecular dissection of Janus kinases as drug targets for inflammatory diseases
por: Kwon, Sunghark
Publicado: (2022)

Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis
por: Guo, Kai, et al.
Publicado: (2019)

Complement Activation in Autoimmune Bullous Dermatoses: A Comprehensive Review
por: Edwards, Gareth, et al.
Publicado: (2019)

Role of Regulatory Immune Cells and Molecules in Autoimmune Bullous Dermatoses
por: Cao, Tianyu, et al.
Publicado: (2019)

Commentary: Janus kinase inhibitors and their use in autoimmune ocular inflammatory disorders
por: Moreker, Mayur R
Publicado: (2020)

Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
por: Quadri, Iman, et al.
Publicado: (2023)

The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury
por: Fang, Hui, et al.
Publicado: (2018)

Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies
por: Hammitzsch, Ariane, et al.
Publicado: (2020)

The Autoimmune Bullous Diseases
por: Wakelin, S H, et al.
Publicado: (1997)

Janus-Faced Myeloid-Derived Suppressor Cell Exosomes for the Good and the Bad in Cancer and Autoimmune Disease
por: Zöller, Margot
Publicado: (2018)

Changes in the molecular profiles of large-vessel vasculitis treated with biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors
por: Matsumoto, Kotaro, et al.
Publicado: (2023)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China
por: Li, Wendao, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019)

Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden
por: Eriksson, Per, et al.
Publicado: (2023)

Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review
por: Wen, Ji, et al.
Publicado: (2021)

Involvement of palms and soles in patients with autoimmune bullous diseases: a comparative analysis of a diagnostically relevant localization
por: Jałowska, Magdalena, et al.
Publicado: (2023)

Therapy of autoimmune bullous diseases
por: Mutasim, Diya F
Publicado: (2007)

Autoimmune Bullous Disease in Childhood
por: Salman, Andac, et al.
Publicado: (2017)

Janus kinase inhibitors: jackpot or potluck?
por: Pavithran, Keechilat, et al.
Publicado: (2012)

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
por: Núñez, Paulina, et al.
Publicado: (2023)

The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: De Vries, L.C.S., et al.
Publicado: (2017)

Targeting heat shock proteins 90 and 70: A promising remedy for both autoimmune bullous diseases and COVID-19
por: Kasperkiewicz, Michael, et al.
Publicado: (2022)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
por: Veale, Douglas J, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2rbvoveifdmmogruu8i4s4fm18